Xingjuan Chao Sells 25,000 Shares of CeriBell, Inc. (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $17.70, for a total value of $442,500.00. Following the completion of the transaction, the chief executive officer directly owned 776,022 shares in the company, valued at approximately $13,735,589.40. This represents a 3.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, June 3rd, Xingjuan Chao sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $17.00, for a total value of $425,000.00.
• On Thursday, May 15th, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $16.96, for a total value of $424,000.00.
• On Wednesday, April 23rd, Xingjuan Chao sold 15,628 shares of CeriBell stock. The shares were sold at an average price of $15.11, for a total value of $236,139.08.
• On Thursday, April 17th, Xingjuan Chao sold 5,700 shares of CeriBell stock. The shares were sold at an average price of $15.02, for a total value of $85,614.00.
• On Monday, April 21st, Xingjuan Chao sold 3,372 shares of CeriBell stock. The shares were sold at an average price of $15.03, for a total value of $50,681.16.

CeriBell Stock Performance

Shares of CBLL stock traded down $0.63 during trading hours on Friday, hitting $16.13. 131,165 shares of the company's stock were exchanged, compared to its average volume of 290,379. The stock's 50-day moving average is $17.52 and its 200-day moving average is $19.65. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.36 and a quick ratio of 16.81. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.49 million for the quarter, compared to the consensus estimate of $19.30 million. Research analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current year.

Hedge Funds Weigh In On CeriBell

Large investors have recently made changes to their positions in the company. Ameriprise Financial Inc. acquired a new position in shares of CeriBell during the fourth quarter valued at $368,000. Corebridge Financial Inc. acquired a new position in shares of CeriBell during the fourth quarter valued at $158,000. PNC Financial Services Group Inc. acquired a new position in shares of CeriBell during the fourth quarter valued at $47,000. Bank of America Corp DE acquired a new position in CeriBell in the fourth quarter valued at about $498,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in CeriBell in the fourth quarter valued at about $10,750,000.

Analyst Ratings Changes

A number of analysts have recently issued reports on CBLL shares. BTIG Research started coverage on CeriBell in a research report on Tuesday, June 24th. They set a "buy" rating and a $30.00 price objective on the stock. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $32.14.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.